SARS-CoV-2

Zhiyi Liao1,2, Chaoming Wang1,2, Xiaopeng Tang1,3

  • 1Engineering Laboratory of Peptides of Chinese Academy of Sciences, Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology-Chinese University of Hong Kong Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, National Research Facility for Phenotypic & Genetic Analysis of Model Animals (Primate Facility), and Sino-African Joint Research Center, New Cornerstone Science Laboratory, Kunming Institute of Zoology, The Chinese Academy of Sciences, Kunming 650201, China.

概括

人类转移素受体 (TfR) 作为SARS-CoV-2的替代入口,独立于ACE2. 针对TfR的目标显示出开发新的COVID-19治疗方法的希望.